There’s something remarkable about a company that not only has been successful commercially but has been supported by the key influential people in the industry. This may be the case with how Herbalife has built its progress, influence and market relevance. Herbalife’s health supplements and its multi-level marketing model have indeed transformed the lives of many people and given different kinds of shareholders the prosperity they want. In fact, Herbalife (HL) has been so influential lately that it has even attracted the support of athletes in the industry today.
One of the few remarkable people in sports that have shown continuous support to the health supplements of Herbalife is no other than the renowned active racer Nicolas Fuchs. Right now, he’s a busy, passionate racer who has made a strong name in rally car driving. His achievement, though, would probably not be that much of a success if he didn’t stick to his proper nutrition and fitness training. Discipline is key here. He had to limit himself to just eating the healthiest products out there. He had to only support the brands in nutrition that provide high value to his entire nutrition plan. And the good thing about HL today is that it contains all the nutrition supplements that racers like him would need to perform well in the field. Fuchs has already made a name in rally car race in 2005 while racing in Peru, and since then he has already given a lot of pride for those who support him. Without his proper nutrition diet, this may not well be possible.
It’s worth mentioning here that HL is a global multi-level marketing that’s highly marketable and highly supported by the global market. In fact, since being founded about 38 years ago in Los Angeles, California, HL is already a household name in the field of weight management and nutritional supplements, among others.
With a net revenue of about US$4.43 billion since 2017 and a total equity of about US$ 468 million in 2016, it’s hard to deny the commercial repute of HL. The 8,000 employees of the company is also a strong mark or indicator that it is a company that’s socially relevant, as companies like HL are needed by any society because they generate jobs.
One major challenge facing the modern world is the high mortality rate caused by diseases. These diseases are mostly chronic illnesses which haven’t had any or significant treatment breakthrough over the decades. This has led medical practitioners to come up with institutions that deal with the development of targeted therapy drug for such diseases. One of the most notable medical practitioners in this area is Dr. Clay Siegall. He is the founder and CEO of a biotech firm based in Seattle, dabbed as Seattle Genetics.
About Seattle Genetics
The firm focuses more on finding significant breakthroughs in medicine. Its way of achieving this, is by continually developing targeted therapy drugs for such diseases. Seattle Genetics was founded in the year 1998, and since then, Dr. Clay Siegall has steered the firm to a remarkable height. The firm developed the first FDA-approved antibody drug conjugate that has over the time received substantial approvals. The firm has strategically partnered with various drug manufacturers such as; Genentech, Pfizer, Bayer among others, in providing a wide range of variety of drugs that have proven to be remarkable. Under his leadership, the firm has seen great improvement in growth. During its early years in the industry the company had very few and not well known researchers. This soon changed over the years and currently it’s among the top players in the Research on Cancer.
Dr. Siegall does not plan to stop there yet, this is because the list of drugs in the development pipeline is still growing and need reliable firms such Seattle Genetics for a breakthrough. The struggle in offering effective treatment against these diseases still prove to be challenging but firms such as Seattle are still keeping up the fight. Dr. Clay Siegall will not stop nor give up on ensuring that we all have a healthier world.
Personal Details on Dr. Siegall
Dr. Siegall has involved himself in capital raising, whereby he managed to secure $675 million through public and private donors who were in support for his work. Early in his life, he previously worked with National Institutes of Health, for a period ranging from 1988 to 1991. He later joined a research institute, where he worked from 1991 to 1997, known as Bristol-myers Squibb Pharmaceutical Research Institute. His reputation and knowledge in his area of expertise allowed him to serve on the board of directors of a private biotechnology company Alder Biopharmaceuticals. In addition, Dr Siegall is an author and holds more than 70 publications and 15 patents under his name. He received his Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He surely is a force to reckon with in this industry.